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IN all areas of medicine, the appropriate use of antimicrobial agents has become a subject of much interest and debate. Concerns over the misuse of antibiotics centre on the possible build up of bacterial resistance and a fear of residues entering the food chain. The veterinary surgeon plays a pivotal role in the way in which antibacterial agents are used on the dairy farms under his/her care and dry cow therapy is probably the most commonly prescribed antibiotic product, with almost 4 tonnes of active ingredients being used in the year 2000. As with all medicines, it is essential that dry cow therapy is prescribed on a rational basis. The aim of this two-part article is to describe current knowledge on udder health in the dry period and to use this to develop a logical approach to prescribing dry cow therapy. Part 2, which will be published in the next issue, will provide guidance on product selection.
PHASES OF THE DRY PERIOD
The dry period is the time between the last milking of one lactation and calving at the start of the next lactation. Research suggests that excessively short (four-week) and long (10-week) dry periods are detrimental to udder health (Enevoldsen and Sorensen 1992) , although 50 to 70 days has been identified as the optimal dry period from the point of view of milk production (see graph below). Decreasing the length of the dry period results in a decreased yield in the subsequent lactation, whereas excessively long dry periods decrease lifetime yields and can lead to problems with cows becoming too fat at calving. The dry period is occasionally lengthened in response to a premature reduction in milk yield or in an attempt to reduce herd milk output because of quota constraints.
During the dry period the mammary gland undergoes a series of changes that influence the cow's resistance to bacterial infection. These are described below.
INVOLUTION
The transition from a lactating to a fully involuted, dry gland can take three to four weeks. For several reasons, this is a time of increased risk of bacterial infection: * There is initially an increase in intramammary pressure when milking stops, and this leads to widening of the streak canal and teat orifice; * The regular removal of milk stops and therefore the physical effect of flushing bacteria that penetrate the mammary gland ceases; * There is a cessation of teat Research has shown that clinical mastitis that arises from infections acquired during the dry period occurs at a faster rate after calving than clinical mastitis arising from infections acquired during lactation (Green and others 2002) . Dry period infections tend to become clinical within one month of calving, whereas clinical mastitis contracted during lactation tends to occur at a more even rate (see graph, above right). This means that plotting the incidence of clinical mastitis and observing the pattern in a herd will give an indication of the impact of dry period infections. Molecular techniques (DNA fingerprinting) have recently been used in the UK to Green and others (2002) follow strains of E coli and other Enterobacteriaceae from the dry period to clinical cases of mastitis, to confirm this link (see below). 
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BASIS FOR PRESCRIBING DRY COW THERAPY
The ultimate aim in prescribing dry cow therapy is to ensure that each cow receives the most suitable dry cow formulation. This requires an understanding of the causes of clinical and subclinical mastitis on a dairy farm and the antibiotics available (these will be discussed in Part 2). A number of techniques can be used to acquire the necessary background information on which to base a logical approach to dry cow therapy, and these are described below.
DRYING OFF: INFECTED VERSUS UNINFECTED COWS
In the modern dairy herd, at the time of drying off a minority of cows will be infected with a major pathogen and the majority will be uninfected. These two groups of cows have different requirements: the aim for infected cows is to cure existing intramammary infections; the aim for uninfected cows is to prevent the acquisition of new intramammary infections. It may therefore be necessary to prescribe two different products to meet the different requirements of the two groups.
Key This can be done in several ways at herd and/or cow levels.
Herd level Performing regular bacteriology on bulk tank samples is simple and relatively cheap, but is not to be recommended as a basis for making decisions on dry cow therapy. This is because identification of a bacterial species in bulk milk does not necessarily mean it has come from an infected quarter -it could be a skin or environmental contaminant. This is certainly true for commonly isolated bacteria such as S uberis, Staphylococcus aureus and E coli; as an 'obligate' udder pathogen, discovery of S agalactiae is of greater significance and will have an influence on many decisions, including that of dry cow therapy. Furthermore, isolation of a bacterial species from bulk tank milk gives no quantitative information regarding the prevalence of infection within the herd. However, the bulk milk somatic cell count will give an indication of the levels of subclinical mastitis in the herd and can be used as an aid to setting priorities for dry cow therapy selection.
Cow level Direct bacterial culture from infected cows provides a specific means of identifying the pathogens involved in subclinical mastitis. Individual cow SCCs will assist in identifying infected cows: an SCC of over 200,000 cells/ml for three consecutive recordings suggests that one or more quarters is likely to be infected. The infected quarter(s) in these cows can then be identified using the Californian Milk Test or individual quarter somatic cell counting.
Bacterial culture of milk samples from infected quarters will often reveal the species involved and this is best performed by an accredited laboratory meeting recognised standards for identification of mastitis pathogens. The selection of cows for sampling is important. To maintain an up-to-date farm picture, it is useful to sample around six to 10 high SCC cows/100 cows/year. Collection of a milk sample * Clean and dry the teats, as necessary, to remove gross contamination * Predip (with proprietary predip solution); allow 30 seconds contact time before drying * Thoroughly clean and disinfect the teat by scrubbing with cotton wool soaked in 70 per cent alcohol, then allow to dry * Strip quarters approximately six times N Again clean and disinfect the teat by scrubbing with cotton wool soaked in 70 per cent alcohol, then allow to dry ONGOING MONITORING Drawing on all of the available records and supplementing this with strategic bacteriology of high SCC cows and clinical cases, it is possible to gain an insight into the epidemiology and aetiology of mastitis on an individual dairy unit. Continued monitoring of the herd in this way is a vital component of rational prescribing of both lactating and dry cow intramammary products.
WE KNOW THE BACTERIA -NOW WHAT?
Knowledge of the main pathogens on a farm helps in deciding on the type(s) of dry cow therapy that are appropriate. This may vary between cows within a herd, * Take milk sample by stripping milk horizontally into a sterile pot. Ensure the pot does not become contaminated by holding it in an inverted position before moving it into a horizontal position to catch the milk * Label the pot immediately after replacing the lid * Carefully administer an intramammary tube, if required, and dip the teat in an effective germicidal product * Confine the cow to a loafing yard/area for approximately 30 minutes to allow closure of the streak canal or even at different times of the year. All this information will be used to derive a logical approach to the prescription of dry cow therapy in Part 2, to be published in the next issue.
